254 related articles for article (PubMed ID: 15841490)
41. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
Sumegi J; Huang D; Lanyi A; Davis JD; Seemayer TA; Maeda A; Klein G; Seri M; Wakiguchi H; Purtilo DT; Gross TG
Blood; 2000 Nov; 96(9):3118-25. PubMed ID: 11049992
[TBL] [Abstract][Full Text] [Related]
42. Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis.
Meazza R; Tuberosa C; Cetica V; Falco M; Parolini S; Grieve S; Griffiths GM; Sieni E; Marcenaro S; Micalizzi C; Montin D; Fagioli F; Moretta A; Mingari MC; Moretta L; Notarangelo LD; Bottino C; Aricò M; Pende D
J Allergy Clin Immunol; 2014 Dec; 134(6):1381-1387.e7. PubMed ID: 24985396
[TBL] [Abstract][Full Text] [Related]
43. The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells.
Nagy N; Mattsson K; Maeda A; Liu A; Székely L; Klein E
Immunol Lett; 2002 Jun; 82(1-2):141-7. PubMed ID: 12008045
[TBL] [Abstract][Full Text] [Related]
44. Defective NK cell activation in X-linked lymphoproliferative disease.
Benoit L; Wang X; Pabst HF; Dutz J; Tan R
J Immunol; 2000 Oct; 165(7):3549-53. PubMed ID: 11034354
[TBL] [Abstract][Full Text] [Related]
45. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses.
Sumegi J; Seemayer TA; Huang D; Davis JR; Morra M; Gross TG; Yin L; Romco G; Klein E; Terhorst C; Lanyi A
Leuk Lymphoma; 2002 Jun; 43(6):1189-201. PubMed ID: 12152986
[TBL] [Abstract][Full Text] [Related]
46. Structural characterization of disease-causing mutations on SAP and the functional impact on the SLAM peptide: a molecular dynamics approach.
Chandrasekaran P; Rajasekaran R
Mol Biosyst; 2014 Jul; 10(7):1869-80. PubMed ID: 24770789
[TBL] [Abstract][Full Text] [Related]
47. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP.
Palendira U; Low C; Chan A; Hislop AD; Ho E; Phan TG; Deenick E; Cook MC; Riminton DS; Choo S; Loh R; Alvaro F; Booth C; Gaspar HB; Moretta A; Khanna R; Rickinson AB; Tangye SG
PLoS Biol; 2011 Nov; 9(11):e1001187. PubMed ID: 22069374
[TBL] [Abstract][Full Text] [Related]
48. Pathogenesis and diagnosis of X-linked lymphoproliferative disease.
Gilmour KC; Gaspar HB
Expert Rev Mol Diagn; 2003 Sep; 3(5):549-61. PubMed ID: 14510176
[TBL] [Abstract][Full Text] [Related]
49. Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors.
Tovar V; del Valle J; Zapater N; Martin M; Romero X; Pizcueta P; Bosch J; Terhorst C; Engel P
Immunogenetics; 2002 Sep; 54(6):394-402. PubMed ID: 12242590
[TBL] [Abstract][Full Text] [Related]
50. Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease.
Wu C; Sayos J; Wang N; Howie D; Coyle A; Terhorst C
Immunogenetics; 2000 Aug; 51(10):805-15. PubMed ID: 10970095
[TBL] [Abstract][Full Text] [Related]
51. Immune regulation by SLAM family receptors and SAP-related adaptors.
Veillette A
Nat Rev Immunol; 2006 Jan; 6(1):56-66. PubMed ID: 16493427
[TBL] [Abstract][Full Text] [Related]
52. Early and rapid detection of X-linked lymphoproliferative syndrome with SH2D1A mutations by flow cytometry.
Zhao M; Kanegane H; Kobayashi C; Nakazawa Y; Ishii E; Kasai M; Terui K; Gocho Y; Imai K; Kiyasu J; Nonoyama S; Miyawaki T
Cytometry B Clin Cytom; 2011 Jan; 80(1):8-13. PubMed ID: 20632414
[TBL] [Abstract][Full Text] [Related]
53. Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation.
Howie D; Simarro M; Sayos J; Guirado M; Sancho J; Terhorst C
Blood; 2002 Feb; 99(3):957-65. PubMed ID: 11806999
[TBL] [Abstract][Full Text] [Related]
54. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection.
Shinozaki K; Kanegane H; Matsukura H; Sumazaki R; Tsuchida M; Makita M; Kimoto Y; Kanai R; Tsumura K; Kondoh T; Moriuchi H; Miyawaki T
Int Immunol; 2002 Oct; 14(10):1215-23. PubMed ID: 12356686
[TBL] [Abstract][Full Text] [Related]
55. A unique clinical presentation of X-linked lymphoproliferative syndrome with a novel mutation in SH2D1A and review of the literature.
Eckrich MJ; Yang E; Domm J; Ho R; Calder C; Manes B; Bleesing J; Frangoul H
J Pediatr Hematol Oncol; 2011 Jan; 33(1):e39-42. PubMed ID: 20975587
[TBL] [Abstract][Full Text] [Related]
56. SH2D1A mutations in Japanese males with severe Epstein-Barr virus--associated illnesses.
Sumazaki R; Kanegane H; Osaki M; Fukushima T; Tsuchida M; Matsukura H; Shinozaki K; Kimura H; Matsui A; Miyawaki T
Blood; 2001 Aug; 98(4):1268-70. PubMed ID: 11493483
[TBL] [Abstract][Full Text] [Related]
57. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance.
Menard L; Cantaert T; Chamberlain N; Tangye SG; Riminton S; Church JA; Klion A; Cunningham-Rundles C; Nichols KE; Meffre E
J Allergy Clin Immunol; 2014 Apr; 133(4):1149-61. PubMed ID: 24373350
[TBL] [Abstract][Full Text] [Related]
58. Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development.
Nagy N; Klein E
Immunol Lett; 2010 May; 130(1-2):13-8. PubMed ID: 20080127
[TBL] [Abstract][Full Text] [Related]
59. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2).
Del Valle JM; Engel P; Martín M
J Biol Chem; 2003 May; 278(19):17430-7. PubMed ID: 12621057
[TBL] [Abstract][Full Text] [Related]
60. [Clinical and gene research of X-linked lymphoproliferative disease in a Chinese family].
Zhu DX; Du J; Lan HK; Yu L; Feng ZC
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):244-8. PubMed ID: 17425868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
